- Home
- MRNO vs IMNM Comparison
MRNO vs IMNM Comparison
Compare MRNO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- IMNM
- Stock Information
- Founded
- MRNO 2021
- IMNM 2006
- Country
- MRNO United Kingdom
- IMNM United States
- Employees
- MRNO N/A
- IMNM N/A
- Industry
- MRNO
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- MRNO
- IMNM Health Care
- Exchange
- MRNO NYSE
- IMNM Nasdaq
- Market Cap
- MRNO 794.8M
- IMNM 806.1M
- IPO Year
- MRNO N/A
- IMNM 2020
- Fundamental
- Price
- MRNO $10.47
- IMNM $6.99
- Analyst Decision
- MRNO
- IMNM Strong Buy
- Analyst Count
- MRNO 0
- IMNM 5
- Target Price
- MRNO N/A
- IMNM $26.60
- AVG Volume (30 Days)
- MRNO 4.4K
- IMNM 1.0M
- Earning Date
- MRNO 05-25-2025
- IMNM 03-19-2025
- Dividend Yield
- MRNO N/A
- IMNM N/A
- EPS Growth
- MRNO N/A
- IMNM N/A
- EPS
- MRNO N/A
- IMNM N/A
- Revenue
- MRNO $27,954,510.00
- IMNM $9,041,000.00
- Revenue This Year
- MRNO N/A
- IMNM N/A
- Revenue Next Year
- MRNO N/A
- IMNM $476.80
- P/E Ratio
- MRNO N/A
- IMNM N/A
- Revenue Growth
- MRNO 211.17
- IMNM N/A
- 52 Week Low
- MRNO $5.70
- IMNM $6.90
- 52 Week High
- MRNO $13.25
- IMNM $24.87
- Technical
- Relative Strength Index (RSI)
- MRNO 43.42
- IMNM 31.33
- Support Level
- MRNO $10.35
- IMNM $6.94
- Resistance Level
- MRNO $11.94
- IMNM $7.68
- Average True Range (ATR)
- MRNO 0.76
- IMNM 0.57
- MACD
- MRNO -0.05
- IMNM -0.14
- Stochastic Oscillator
- MRNO 10.32
- IMNM 3.47
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.